SU SURAKSHA
Suraksha Diagnostic Q2 2026
SUSURAKSHA

Suraksha Diagnostic Q2 FY26 results (Jul–Sep 2025) and concall

Healthcare · Concall AI · Call held 11 Nov 2025

Management summary

  • Suraksha Diagnostic Limited reported strong revenue growth in Q2 and H1 FY26, driven by network expansion and sustained demand.
  • However, profitability metrics like EBITDA and PAT margins were impacted in Q2 due to adverse weather conditions and early festivities.
  • The company continues its strategic investment in new centers and genomics, expecting long-term margin expansion as these centers mature.
  • Facing short-term pressure on realization per test due to discounts and B2B mix..

Source: Inve concall analysis and management guidance record.

Highlights

  • Total income for Q2 FY26 stood at INR79.58 crores, showing a growth of 16.9% year-on-year.

  • H1 FY26 revenue reached INR153.072 crores, marking a 17.8% year-over-year increase.

  • Network grew to 63 centers by the end of September 2025, including 3 new centers added in Q2 FY26.

  • Successfully launched Suraksha Genomics, a landmark event for advanced genetic and molecular testing services.

Why these two revenue figures differ: Management cited ₹153.1 Cr (Revenue) on the call, while the exchange-filed quarterly statement below reports ₹76 Cr — typically due to standalone vs. consolidated scope, revenue from operations vs. total income (including other income), or presentation adjustments.

What they filed

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26Q2 FY26
Revenue59 64 70 76
EBITDA18 20 24 24
Net profit6 8 10 9
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Revenue

  • Revenue Growth Revenue · FY26 · High confidence 15%

Profitability

  • EBITDA Margin Profitability · FY26 · High confidence 33% to 34%

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

2 direct
Realization per test reduction Direct
So, this is because like you rightly mentioned, we do give discounts in the new centers that we set up to for traction of patients. That is one. And second is we have increased our B2B business, if you will see by 1%, and that normally consists of packages. Therefore, realization

Analyst questioned the decline in realization per test from INR389 to INR364, and management explained it was due to new center discounts and increased B2B business.

Asked by Mihir Singh

Increase in other expenses Direct
So normally, our other expenses as a percentage of sales, which ranges from 35% to 37%, 38%. So current quarter, we are at 40.5%. So, if you proportionately, if your sales -- if you consider the expenses, we have increased by around INR4 crores, the INR4 crores is mainly due to t

Analyst inquired about the INR4 crore increase in other expenses, and management provided a detailed breakdown, attributing it to rental expenses, professional fees to doctors, post-listing charges, and administrative expenses for new centers.

Asked by Mihir Singh

Unlock risks & concerns, Q3 FY26 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 8 risks, concerns & management red flags
  • 5 watchlist triggers for Q3 FY26
  • +9 more guidance targets & verbatim management quotes
  • +6 more analyst Q&A exchanges & evasion checks
  • Capital allocation & full section-by-section narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image